• Evoke Pharma Inc., of San Diego, selected Synteracthcr Inc. to serve as its primary contract research organization for its upcoming Phase III trial with EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.